Login / Signup

Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.

Jinzhu MaoDongxu WangJunyu LongXu YangJianzhen LinYiwei SongFucun XieZiyu XunYanyu WangYunchao WangYiran LiHuishan SunJingnan XueYang SongBangyou ZuoJunwei ZhangJin BianTing ZhangXiaobo YangLei ZhangXinting SangHaitao Zhao
Published in: Journal for immunotherapy of cancer (2022)
We demonstrate that the gut microbiome is associated with the clinical response to anti-PD-1 immunotherapy in patients with hepatobiliary cancers. Taxonomic signatures enriched in responders are effective biomarkers to predict the clinical response and survival benefit of immunotherapy, which might provide a new therapeutic target to modulate the response to cancer immunotherapy.
Keyphrases
  • dna methylation